Mekinist (Trametinib)

Trametinib selectively blocks the activity of MEK1 and MEK2 kinases, which are key components of the MAPK/ERK signaling pathway. By inhibiting MEK, the drug prevents downstream signals that promote cancer cell proliferation and survival, thereby slowing or stopping tumor growth in cancers with activated MAPK signaling.

The specific dose of Mekinist is determined by the prescribing physician based on the patient’s clinical condition, weight, and other factors. Dosage instructions are provided on the prescription label and should be followed exactly as directed by the healthcare professional.

The safety of trametinib in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To request Mekinist, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mekinist (trametinib) is a selective MEK1/2 inhibitor with a well‑characterized safety profile. Compared with other MEK inhibitors, it offers similar efficacy in BRAF‑mutated cancers but may differ in the incidence of specific side effects such as skin rash or ocular events. Choice of therapy depends on clinical judgment and patient tolerance.

Mekinist tablets should be stored at room temperature, below 25 °C, in the original blister pack. Keep the medication away from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Mekinist is taken orally as a tablet, usually once daily, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their oncologist. Consistency in timing helps maintain steady drug levels.

Serious risks include interstitial lung disease, cardiac dysfunction (reduced left‑ventricular ejection fraction), severe hepatic injury, and ocular toxicity such as retinal disorders. Patients should be monitored regularly for respiratory symptoms, cardiac changes, liver function abnormalities and visual disturbances.

Mekinist is contraindicated in patients with known hypersensitivity to trametinib or any of its excipients. It should be used with caution in individuals with pre‑existing cardiac, hepatic or ocular conditions, and it is generally avoided in pregnant or breastfeeding women due to unknown safety.